Showing 2251-2260 of 4063 results for "".
- Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-to-enter-clinic-with-treatment-for-dry-amd/2481974/Inflammasome Therapeutics, developer of a new class of inflammasome inhibitor drugs called Kamuvudines, announced the FDA has granted approval for the opening of a phase 1/2 clinical trial of the company’s drug for the treatment of geographic atrophy (GA). This is the first clinical tr
- Kiora’s KIO-301 Molecular Photoswitch Evaluated for Retinitis Pigmentosa in ABACUShttps://modernod.com/news/kioras-kio-301-molecular-photoswitch-evaluated-for-retinitis-pigmentosa-in-abacus/2481946/Kiora Pharmaceuticals announced topline results of a phase 1/2 clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class intravitreal (IVT) molecular photoswitch, has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP)
- Belite Bio’s Tinlarebant Studied to Treat Childhood-onset Stargardt Diseasehttps://modernod.com/news/belite-bios-tinlarebant-studied-to-treat-childhood-onset-stargardt-disease/2481950/Belite Bio presented final data from a 24-month, phase 2 study of Tinlarebant (LBS-008) in adolescent Stargardt disease (STGD1). The study—LBS-008-CT02—enrolled 12 adolescent STGD1 patients, aged 12-18 years, who completed
- Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophyhttps://modernod.com/news/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-atrophy/2481911/Annexon announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The EMA granted this designation based on the phase 2 ARCHER
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-
- Prevent Blindness to Host “World Sight Day” Congressional Briefing and Free Vision Screening on Capitol Hillhttps://modernod.com/news/prevent-blindness-to-host-world-sight-day-congressional-briefing-and-free-vision-screening-on-capitol-hill/2481872/Nonprofit Prevent Blindness will be hosting a Congressional Briefing and free vision screening on October 12 from 10 am to 2 pm ET. The event, with support from the Prevention of Blindness Society of Metropolitan Washington, is part of this year’s
- Two-Year Results of Eylea HD (Aflibercept 8 mg) from PULSAR Trial for Wet AMD Presented at Euretinahttps://modernod.com/news/two-year-results-of-eylea-hd-aflibercept-8-mg-from-pulsar-trial-presented-at-euretina/2481870/Regeneron announced the first presentation of positive 2-year (96 weeks) results from the PULSAR trial investigating Eylea HD (aflibercept) injection 8 mg with 12- and 16-week dosing regimens, compared to Eylea (aflibercept) injection, in patients with wet age-related macular degenerati
- Viatris Launches First National Direct to Consumer Campaign for Dry Eye Nasal Spray Tyrvayahttps://modernod.com/news/viatris-launches-first-national-direct-to-consumer-campaign-for-dry-eye-nasal-spray-tyrvaya/2481860/After nearly 2 years of educational programs to introduce Tyrvaya (varenicline solution) Nasal Spray to eye care professionals, the Viatris Eye Care Division announced it is rolling out a nationwide, multi-channel campaign. The new campaign, entitled “It’s Not Another Drop,&
- Novartis to Discontinue Development of GA Gene Therapyhttps://modernod.com/news/novartis-to-discontinue-development-of-ga-gene-therapy/2481824/Following weak phase 2 clinical data, Novartis decided to discontinue the clinical development of its geographic atrophy gene therapy candidate GT005, which it acquired as part of its acquisition of Gyroscope Therapeutics. The announcement was made by investment film Syncona, which prev
- Cognition Therapeutics Doses First Patient in MAGNIFY Study of Oral CT1812 for GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-dosing-of-first-patient-in-magnify-study-of-oral-ct1812-for-ga-secondary-to-dry-amd/2481714/Cognition Therapeutics announced that it has dosed the first participant in the phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The MAGNIFY study (COG2201,